Page 1226 - Adams and Stashak's Lameness in Horses, 7th Edition

1192 Index

infraspinatus bursa podotrochlear (navicular) bursa, 169–172 physiologic trauma leading to
osteoarthritis, 809
inflammation, 643–644 proximal interphalangeal (PIP) joint (high synovitis and capsulitis, 809–810
ringbone), 172, 173
clinical signs, 644
VetBooks.ir diagnosis, 644 sacroiliac (SI) joint, 186–187 synovitis importance, 810–813
scapulohumeral (shoulder) joint, 180–181
etiology, 644
traumatic arthritis: multiple
prognosis, 644
craniolateral approach, 180
manifestations, 808–809
lateral approach, 180
treatment, 644
intermittent upward fixation of the patella, stifle joint, 183–185 subchondral bone primary disease,
816–817
jumping/eventing/dressage, 996 femoropatellar joint, 184 ultrasonography, 324–331
intersesamoidean ligament injuries, magnetic lateral femorotibial (LFT) joint, 185 articular cartilage and subchondral bone
resonance imaging (MRI), 414 medial femorotibial (MFT) joint, surface, 328
intertarsal ligament injury, tarsal region, 184–185 equipment and technique, 324–325
magnetic resonance imaging single approach for all three joints, 185 identifying incomplete ossification, 331
(MRI), 423 tarsal (hock) joints, 181–183 immature cartilage and bone, 328
intertubercular bursa (bicipital bursitis) distal intertarsal (DIT) or centrodistal indications for ultrasonography of
inflammation, 641–643 joint, 182–183 joints, 324
clinical signs, 641 tarsocrural joint, 181–182 joint capsule, 327
conservative treatment, 642–643 tarsometatarsal (TMT) joint, 182 joint injury assessment, 323–324
diagnosis, 641–642 trochanteric bursa, 185–186 menisci, 329–331, 331
etiology, 641 intrasynovial therapies, 886–892 normal variations, 328
prognosis, 643 autologous conditioned serum (ACS), 890 osteoarthritis (OA), 328–329
surgical treatment, 643 autologous protein solution (APS), 891 osteochondral lesions, 328, 329
treatment, 642–643 betamethasone (BA), 888 subchondral bone cystic lesions, 329, 330
intervertebral thoracolumbar facet OA, back bone marrow‐derived mesenchymal stem synovial fluid, 327
pain, jumping/eventing/dressage, 995 cells (BMSCs), 891 synovium, 327
intra‐articular acetabular fractures, 758–759 clinical choices, 887–888 ultrasonic appearance of the joint,
clinical signs, 759 corticosteroid and HA combinations, 889 327–331
diagnosis, 759 corticosteroids (CS), 886–888 ultrasonographic appearance of
etiology, 759 detrimental effects and concerns periarticular structures, 326
prognosis, 759 regarding intra‐articular jumping/eventing/dressage, 986–996
treatment, 759 corticosteroids, 886–887 axial skeleton pain, 994–995
intralesional therapies, 896–898 mechanism of action, 886 back pain, 994–995
autologous bone marrow aspirate fat‐derived mesenchymal stem cells dorsal spinous process impingement,
(ABMA), 896–898 (MSCs), 891 994–995
autologous cell therapies: mesenchymal hyaluronan (or hyaluronic acid, HA), intervertebral thoracolumbar facet
stem cell therapy, autologous bone 888–889 OA, 995
marrow aspirate, tendon‐derived methylprednisolone acetate (MPA), kissing spines, 994–995
progenitor cells, 896–897 887–888 primary muscle strain and or spasm, 994
autologous protein solution (APS), 897–898 platelet‐rich plasma (PRP), 890–891 suboptimal saddle fit creating pressure
blood‐derived biologics: platelet‐rich polyacrylamide hydrogel (PAAG), 891–892 points or restricting the horse’s
plasma, autologous conditioned Polyglycan 890 movement, 994
®
serum, autologous protein solution, polysulfated glycosaminoglycans cervical pain, 994
and bone marrow aspirate, 897–898 (PSGAGs), 889–890 common lameness problems, 991–996
corticosteroids (CS), 898 practical considerations, 892 foot pain, 991–992
hyaluronan and polysulfated triamcinolone acetonide (TA), 887 deep digital flexor tendon (DDFT),
glycosaminoglycans, 896 intravenous regional limb perfusions (IVRLPs), 991–992
mesenchymal stem cell (MSC) therapy, topical/local therapies, 882–883 distal interphalangeal (DIP) joint,
896–897 ipsilateral gaits, lameness evaluation, 135–136 991–992
platelet‐rich plasma (PRP), 897–898 IVRLPs (intravenous regional limb heel pain and solar pain, 991
sarapin, 898 perfusions), topical/local therapies, navicular syndrome, 991–992
tendon‐derived progenitor cells, 896–897 882–883 horses used for the disciplines, 986–987
intrasynovial anesthesia, 167–187 inferior check ligament desmitis, 995–996
bicipital bursa, 180–181 joint angle measurements associated with lameness diagnosis, 990–991
distal approach, 180–181 lameness, 134 lower hock joint OA, 992–993
proximal approach, 181 joint capsule, ultrasonography, 327 metacarpophalangeal and
calcaneal bursa, 183, 184 joint diseases, thermography, 433–434, 435 metatarsophalangeal (MCP/MTP)
carpal joints, 176–178 joint mobilization and manipulation, manual joint injuries, 996
cervical facets, 186–187 therapy, 926–927 proximal suspensory desmitis (PSD),
coxofemoral (hip) joint, 186 joints, 801–817 993–994
cunean bursa, 183 see also articular sacroiliac pain, 995
digital flexor tendon sheath (DFTS), anatomy and physiology, 801–808 stifle injuries, 996
174–176 articular cartilage metabolism and intermittent upward fixation of the
distal interphalangeal (DIP) joint, 168–169, matrix turnover, 806–807 patella, 996
170–171 articular cartilage structure and function, osteochondrosis and subchondral bone
elbow joint, 178–180 803–806 cysts, 996
caudal approach, 179–180 classification, 801 patellar fractures, 996
caudolateral approach, 179 general anatomy, 801–802 synovitis and OA, 996
lateral approach, 179 lubrication of joints, 807–808 structure of training and competition,
fetlock, 172–174, 175, 176 subchondral bone, 808 987–989
general technique: site preparation, restraint, synovial membrane structure and superficial digital flexor tendon (SDFT),
and interpretation, 167–168, 169 function, 802–803 injury, 995
guidelines, 169 pathobiology of joints and their reaction to suspensory ligament desmitis, 993–994
metacarpophalangeal/metatarsophalangeal insult and injury, 808–816 training surfaces and shoeing, 989–990
(fetlock) joints, 172–174 articular cartilage repair, 814–816
collateral sesamoidean approach, 174, 175 athletic activity potentially leading to a keratoma
distal palmar/plantar approach, 174, 175 pathologic process, 809 foot, 483–485
dorsal approach, 174, 176 pathways to morphologic breakdown of clinical signs, 484
proximal palmar/plantar pouch, articular cartilage: the critical diagnosis, 484, 485
173–174, 175 manifestation of OA, 813–814 etiology, 484